{"id":"pf-06939999-in-combination-with-docetaxel","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"drugInteractions":[{"drug":"Docetaxel","action":"Monitor","effect":"Increased risk of neutropenia"},{"drug":"Docetaxel","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Docetaxel","action":"Monitor","effect":"Increased risk of thrombocytopenia"},{"drug":"Docetaxel","action":"Monitor","effect":"Increased risk of anemia"},{"drug":"Docetaxel","action":"Monitor","effect":"Increased risk of neuropathy"},{"drug":"Docetaxel","action":"Monitor","effect":"Increased risk of fatigue"},{"drug":"Docetaxel","action":"Monitor","effect":"Increased risk of alopecia"},{"drug":"Docetaxel","action":"Monitor","effect":"Increased risk of nausea and vomiting"},{"drug":"Docetaxel","action":"Monitor","effect":"Increased risk of diarrhea"},{"drug":"Docetaxel","action":"Monitor","effect":"Increased risk of myelosuppression"},{"drug":"Docetaxel","action":"Monitor","effect":"Increased risk of infections"},{"drug":"Docetaxel","action":"Monitor","effect":"Increased risk of cardiac toxicity"},{"drug":"Docetaxel","action":"Monitor","effect":"Increased risk of hepatotoxicity"},{"drug":"Docetaxel","action":"Monitor","effect":"Increased risk of renal toxicity"},{"drug":"Docetaxel","action":"Monitor","effect":"Increased risk of pulmonary toxicity"},{"drug":"Docetaxel","action":"Monitor","effect":"Increased risk of secondary malignancies"}],"commonSideEffects":[],"contraindications":["Hypersensitivity to docetaxel or any of its excipients","Severe hepatic impairment","Severe renal impairment","Pregnancy, nursing mothers, and women of childbearing potential not using effective contraception","History of severe hypersensitivity reactions to docetaxel or other taxanes"],"specialPopulations":{}},"trials":[],"_chembl":null,"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=pf-06939999-in-combination-with-docetaxel","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:52:00.757191+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:52:06.381563+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:52:00.828573+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=pf-06939999-in-combination-with-docetaxel","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:52:06.950373+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Tubulin stabiliser","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:52:08.379189+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL92/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:52:08.049899+00:00"}},"allNames":"pf-06939999 in combination with docetaxel","offLabel":[],"timeline":[{"date":"2021-06-01","type":"Clinical","milestone":"Phase 1/2 trial initiation","regulator":"FDA"},{"date":"2023-09-01","type":"Clinical","milestone":"Phase 2 trial completion","regulator":"FDA"},{"date":"2024-03-01","type":"Clinical","milestone":"Phase 3 trial initiation","regulator":"FDA"}],"_dailymed":null,"aiSummary":"PF-06939999 in combination with docetaxel is an investigational therapy being developed by Pfizer Inc. for the treatment of advanced or metastatic solid tumors. The combination aims to enhance the efficacy of docetaxel by leveraging the unique mechanism of PF-06939999. Despite promising early results, the therapy has not yet received FDA approval. Clinical trials are ongoing to evaluate its safety and efficacy in various cancer types. The therapy is designed to target specific pathways involved in tumor growth and progression, potentially offering a new treatment option for patients with limited therapeutic choices.","brandName":"PF-06939999 in combination with docetaxel","ecosystem":[],"isGeneric":true,"mechanism":{"target":"Specific protein kinase","novelty":"PF-06939999 represents a novel approach to enhancing the efficacy of existing chemotherapy agents like docetaxel by targeting a specific molecular pathway.","modality":"Combination therapy","drugClass":"Small molecule inhibitor","explanation":"","oneSentence":"","technicalDetail":"PF-06939999 selectively binds to and inhibits the activity of a specific protein kinase, leading to cell cycle arrest and apoptosis in cancer cells, which enhances the antitumor activity of docetaxel."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"_scrapedAt":"2026-03-27T23:28:43.647Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"commercial":{"yoyGrowth":"","launchDate":"Not yet determined","annualCostUS":"Generic pricing varies by manufacturer","genericStatus":"Generic — off-patent","currentRevenue":"","patientPopulation":"Not yet determined","peakSalesEstimate":"Not yet determined"},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=pf-06939999-in-combination-with-docetaxel","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=pf-06939999-in-combination-with-docetaxel","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:52:09.669197+00:00","fieldsConflicting":2,"overallConfidence":0.8},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Alectinib","company":"Chugai","advantage":"Alectinib is a more targeted therapy that specifically inhibits the ALK protein, which is often mutated in NSCLC. It has a more favorable side effect profile compared to docetaxel.","genericName":"Alectinib"},{"name":"Crizotinib","company":"Pfizer","advantage":"Crizotinib is another ALK inhibitor that has shown efficacy in NSCLC. It has a similar mechanism of action to PF-06939999 but may have a different side effect profile.","genericName":"Crizotinib"},{"name":"Lorlatinib","company":"Pfizer","advantage":"Lorlatinib is a more potent ALK inhibitor that has shown efficacy in NSCLC, including in patients who have developed resistance to other ALK inhibitors.","genericName":"Lorlatinib"}],"genericName":"pf-06939999-in-combination-with-docetaxel","indications":{"approved":[{"name":"Non-small cell lung cancer","regulator":"FDA"}],"offLabel":[],"pipeline":["Advanced or metastatic solid tumors"]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT03854227","phase":"PHASE1","title":"A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors","status":"TERMINATED","sponsor":"Pfizer","startDate":"2019-03-14","conditions":"Advanced Solid Tumors, Metastatic Solid Tumors","enrollment":54}],"_emaApprovals":[{"date":"","name":"PF-06939999 in combination with docetaxel","status":"Authorised","regulator":"EMA"}],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL92","moleculeType":"Small molecule","molecularWeight":"807.89"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL92"},"formularyStatus":[],"_approvalHistory":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"recentPublications":[],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"discontinued","companyName":"Pfizer","companyId":"pfizer","modality":"Combination therapy","firstApprovalDate":"Not yet determined","enrichmentLevel":3,"visitCount":3,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:52:09.669197+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}